Oncology Payment Models

Oncology VBC activity is shifting from model design theory toward infrastructure and risk enablement: community oncology groups appear willing to pursue more prospective, outcomes-oriented arrangements, but continue to face barriers around care-navigation funding, data integration, drug-cost volatility, and administrative burden—issues that will shape participation in any successor oncology payment models from CMS/CMMI under the Trump administration. Private capital is also positioning around oncology enablement, with Thyme Care’s $125M raise and new parent entity signaling payer and investor demand for scalable oncology care-management platforms that can support delegated-risk, total-cost-of-care, and specialty-population health strategies. For ACOs, payers, and health systems, the near-term tension is whether oncology models can move beyond episode-based savings to durable infrastructure for community practices while managing high-cost therapeutics and AI-enabled workflow demands (AJMC on value-based oncology design; Thyme Care raise).